Companies › NEOK Bio
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NEOK001 B7-H3 and ROR1 targeting bispecific antibody-drug conjugate | B7H3, ROR1 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Jan 2029 |
| NEOK002 EGFR and MUC1-targeting bispecific antibody-drug conjugate (ADC) | EGFR, MUC1 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07612176 | NEOK001 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Oncology | Jan 2029 |
| NCT07612189 | NEOK002 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Oncology | Feb 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.